Corcept Therapeutics Incorporated CORT
116.10
(2.41)
(2.03%)
as of 25 Sep
- Market cap
- $12.9B
- P/E
- 223×
Follow CORT
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
83.11 | 37.02 | 89.58 | 167.21 |
P/S ratio |
11.61 | 4.75 | 5.47 | 11.03 | |
P/FCF ratio |
52.69 | 25.49 | 35.04 | 85.69 | |
P/Operating CF |
157.96 | 94.01 | (251.00) | 273.16 | |
P/B ratio |
13.62 | 5.58 | 6.60 | 12.98 | |
Price to Tangible BV |
13.62 | 5.58 | 6.60 | 12.98 | |
EV/Sales |
11.05 | 4.27 | 5.04 | 10.66 | |
EV/EBITDA |
144.94 | 78.09 | 0.00 | 2,380.33 | |
EV/Operating CF |
50.06 | 22.87 | 32.19 | 80.76 | |
EV/FCF |
50.14 | 22.90 | 32.27 | 82.86 | |
Quick Ratio |
2.85 | 2.60 | 2.53 | 2.50 | |
Current Ratio |
3.14 | 2.92 | 2.86 | 2.86 | |
Net Debt/EBITDA |
(38.93) | 2,739.77 | 6.90 | (7.31) | |
Debt/Assets |
0.64% | 0.60% | 0.00% | 0.00% | |
Debt/Equity |
0.01 | 0.01 | 0.00 | 0.00 | |
Asset Turnover |
0.92 | 0.91 | 0.93 | 0.98 | |
Operating CF/Net income |
2.81 | 1.61 | 0.54 | 0.80 | |
Capex/Depreciation |
0.00 | 0.01 | (0.34) | (2.93) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
33.16% | 32.09% | 40.18% | 21.04% | |
Selling, General and Administrative Expense of Revenue |
59.71% | 64.43% | 88.15% | 61.25% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.02% | 10.27% | 13.97% | 11.48% | |
Graham Net Nets |
0.04 | 0.08 | 0.06 | 0.03 | |
Graham Number |
11.72 | 11.49 | 7.86 | 8.85 | |
Earnings Yield |
1.20% | 2.70% | 1.12% | 0.60% | |
Free Cash Flow Yield |
1.90% | 3.92% | 2.85% | 1.17% | |
Revenue per Share |
2.01 | 1.95 | 1.58 | 2.43 | |
Operating CF per Share |
0.53 | 0.37 | (0.16) | 0.32 | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
0.53 | 0.37 | (0.16) | 0.29 | |
Cash per Share |
4.07 | 3.58 | 3.24 | 2.92 | |
Shareholders Equity per Share |
6.10 | 6.24 | 6.11 | 6.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.10 | 6.24 | 6.11 | 6.70 | |
Free Cash Flow |
54.48 | 38.40 | (16.97) | 31.02 | |
Working Capital |
368.87 | 319.38 | 276.85 | 285.87 | |
Capital Expenditures |
0.00 | (0.05) | (0.20) | (2.53) | |
Net Current Asset Value |
349.43 | 296.62 | 249.14 | 256.75 | |
EV/EBIT |
124.89 | 72.49 | 0.00 | 1,383.23 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Net Profit Margin |
9.32% | 11.83% | (18.92%) | 16.45% | |
Price to Operating Income |
131.24 | 80.68 | 0.00 | 1,430.53 | |
| Other line items | |||||
Average Receivables |
64.67 | 56.88 | 50.45 | 70.74 | |
Average Payables |
26.52 | 27.91 | 30.63 | 19.22 | |
Average Inventory |
10.20 | 12.64 | 13.63 | 12.73 | |
Average Assets |
803.93 | 838.60 | 830.67 | 845.21 | |
Average Common Equity |
635.37 | 663.70 | 660.64 | 670.78 |
Columns are period end dates